Cargando…
Co-Stimulatory Bispecific Antibodies Induce Enhanced T Cell Activation and Tumor Cell Killing in Breast Cancer Models
Although T cell-recruiting CD3-binding bispecific antibodies (BiMAb) have been proven to be clinically effective for hematologic malignancies, the success of BiMAb targeting solid tumor-associated antigens (TAA) in carcinomas so far remains poor. We reasoned that provision of co-stimulatory BiMAb in...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415424/ https://www.ncbi.nlm.nih.gov/pubmed/34484225 http://dx.doi.org/10.3389/fimmu.2021.719116 |
_version_ | 1783747967683919872 |
---|---|
author | Warwas, Karsten M. Meyer, Marten Gonçalves, Márcia Moldenhauer, Gerhard Bulbuc, Nadja Knabe, Susanne Luckner-Minden, Claudia Ziegelmeier, Claudia Heussel, Claus Peter Zörnig, Inka Jäger, Dirk Momburg, Frank |
author_facet | Warwas, Karsten M. Meyer, Marten Gonçalves, Márcia Moldenhauer, Gerhard Bulbuc, Nadja Knabe, Susanne Luckner-Minden, Claudia Ziegelmeier, Claudia Heussel, Claus Peter Zörnig, Inka Jäger, Dirk Momburg, Frank |
author_sort | Warwas, Karsten M. |
collection | PubMed |
description | Although T cell-recruiting CD3-binding bispecific antibodies (BiMAb) have been proven to be clinically effective for hematologic malignancies, the success of BiMAb targeting solid tumor-associated antigens (TAA) in carcinomas so far remains poor. We reasoned that provision of co-stimulatory BiMAb in combination with αTAA–αCD3 BiMAb would boost T cell activation and proliferative capacity, and thereby facilitate the targeting of weakly or heterogeneously expressed tumor antigens. Various αTAA–αCD3 and αTAA–αCD28 BiMAb in a tetravalent IgG1-Fc based format have been analyzed, targeting multiple breast cancer antigens including HER2, EGFR, CEA, and EpCAM. Moreover, bifunctional fusion proteins of αTAA–tumor necrosis factor ligand (TNFL) superfamily members including 4-1BBL, OX40L, CD70 and TL1A have been tested. The functional activity of BiMAb was assessed using co-cultures of tumor cell lines and purified T cells in monolayer and tumor spheroid models. Only in the presence of tumor cells, αTAA–αCD3 BiMAb activated T cells and induced cytotoxicity in vitro, indicating a strict dependence on cross-linking. Combination treatment of αTAA–αCD3 BiMAb and co-stimulatory αTAA–αCD28 or αTAA–TNFL fusion proteins drastically enhanced T cell activation in terms of proliferation, activation marker expression, cytokine secretion and tumor cytotoxicity. Furthermore, BiMAb providing co-stimulation were shown to reduce the minimally required dose to achieve T cell activation by at least tenfold. Immuno-suppressive effects of TGF-β and IL-10 on T cell activation and memory cell formation could be overcome by co-stimulation. BiMAb-mediated co-stimulation was further augmented by immune checkpoint-inhibiting antibodies. Effective co-stimulation could be achieved by targeting a second breast cancer antigen, or by targeting fibroblast activation protein (FAP) expressed on another target cell. In tumor spheroids derived from pleural effusions of breast cancer patients, co-stimulatory BiMAb were essential for the activation tumor-infiltrating lymphocytes and cytotoxic anti-tumor responses against breast cancer cells. Taken together we showed that co-stimulation significantly potentiated the tumoricidal activity of T cell-activating BiMAb while preserving the dependence on TAA recognition. This approach could provide for a more localized activation of the immune system with higher efficacy and reduced peripheral toxicities. |
format | Online Article Text |
id | pubmed-8415424 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84154242021-09-04 Co-Stimulatory Bispecific Antibodies Induce Enhanced T Cell Activation and Tumor Cell Killing in Breast Cancer Models Warwas, Karsten M. Meyer, Marten Gonçalves, Márcia Moldenhauer, Gerhard Bulbuc, Nadja Knabe, Susanne Luckner-Minden, Claudia Ziegelmeier, Claudia Heussel, Claus Peter Zörnig, Inka Jäger, Dirk Momburg, Frank Front Immunol Immunology Although T cell-recruiting CD3-binding bispecific antibodies (BiMAb) have been proven to be clinically effective for hematologic malignancies, the success of BiMAb targeting solid tumor-associated antigens (TAA) in carcinomas so far remains poor. We reasoned that provision of co-stimulatory BiMAb in combination with αTAA–αCD3 BiMAb would boost T cell activation and proliferative capacity, and thereby facilitate the targeting of weakly or heterogeneously expressed tumor antigens. Various αTAA–αCD3 and αTAA–αCD28 BiMAb in a tetravalent IgG1-Fc based format have been analyzed, targeting multiple breast cancer antigens including HER2, EGFR, CEA, and EpCAM. Moreover, bifunctional fusion proteins of αTAA–tumor necrosis factor ligand (TNFL) superfamily members including 4-1BBL, OX40L, CD70 and TL1A have been tested. The functional activity of BiMAb was assessed using co-cultures of tumor cell lines and purified T cells in monolayer and tumor spheroid models. Only in the presence of tumor cells, αTAA–αCD3 BiMAb activated T cells and induced cytotoxicity in vitro, indicating a strict dependence on cross-linking. Combination treatment of αTAA–αCD3 BiMAb and co-stimulatory αTAA–αCD28 or αTAA–TNFL fusion proteins drastically enhanced T cell activation in terms of proliferation, activation marker expression, cytokine secretion and tumor cytotoxicity. Furthermore, BiMAb providing co-stimulation were shown to reduce the minimally required dose to achieve T cell activation by at least tenfold. Immuno-suppressive effects of TGF-β and IL-10 on T cell activation and memory cell formation could be overcome by co-stimulation. BiMAb-mediated co-stimulation was further augmented by immune checkpoint-inhibiting antibodies. Effective co-stimulation could be achieved by targeting a second breast cancer antigen, or by targeting fibroblast activation protein (FAP) expressed on another target cell. In tumor spheroids derived from pleural effusions of breast cancer patients, co-stimulatory BiMAb were essential for the activation tumor-infiltrating lymphocytes and cytotoxic anti-tumor responses against breast cancer cells. Taken together we showed that co-stimulation significantly potentiated the tumoricidal activity of T cell-activating BiMAb while preserving the dependence on TAA recognition. This approach could provide for a more localized activation of the immune system with higher efficacy and reduced peripheral toxicities. Frontiers Media S.A. 2021-08-16 /pmc/articles/PMC8415424/ /pubmed/34484225 http://dx.doi.org/10.3389/fimmu.2021.719116 Text en Copyright © 2021 Warwas, Meyer, Gonçalves, Moldenhauer, Bulbuc, Knabe, Luckner-Minden, Ziegelmeier, Heussel, Zörnig, Jäger and Momburg https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Warwas, Karsten M. Meyer, Marten Gonçalves, Márcia Moldenhauer, Gerhard Bulbuc, Nadja Knabe, Susanne Luckner-Minden, Claudia Ziegelmeier, Claudia Heussel, Claus Peter Zörnig, Inka Jäger, Dirk Momburg, Frank Co-Stimulatory Bispecific Antibodies Induce Enhanced T Cell Activation and Tumor Cell Killing in Breast Cancer Models |
title | Co-Stimulatory Bispecific Antibodies Induce Enhanced T Cell Activation and Tumor Cell Killing in Breast Cancer Models |
title_full | Co-Stimulatory Bispecific Antibodies Induce Enhanced T Cell Activation and Tumor Cell Killing in Breast Cancer Models |
title_fullStr | Co-Stimulatory Bispecific Antibodies Induce Enhanced T Cell Activation and Tumor Cell Killing in Breast Cancer Models |
title_full_unstemmed | Co-Stimulatory Bispecific Antibodies Induce Enhanced T Cell Activation and Tumor Cell Killing in Breast Cancer Models |
title_short | Co-Stimulatory Bispecific Antibodies Induce Enhanced T Cell Activation and Tumor Cell Killing in Breast Cancer Models |
title_sort | co-stimulatory bispecific antibodies induce enhanced t cell activation and tumor cell killing in breast cancer models |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415424/ https://www.ncbi.nlm.nih.gov/pubmed/34484225 http://dx.doi.org/10.3389/fimmu.2021.719116 |
work_keys_str_mv | AT warwaskarstenm costimulatorybispecificantibodiesinduceenhancedtcellactivationandtumorcellkillinginbreastcancermodels AT meyermarten costimulatorybispecificantibodiesinduceenhancedtcellactivationandtumorcellkillinginbreastcancermodels AT goncalvesmarcia costimulatorybispecificantibodiesinduceenhancedtcellactivationandtumorcellkillinginbreastcancermodels AT moldenhauergerhard costimulatorybispecificantibodiesinduceenhancedtcellactivationandtumorcellkillinginbreastcancermodels AT bulbucnadja costimulatorybispecificantibodiesinduceenhancedtcellactivationandtumorcellkillinginbreastcancermodels AT knabesusanne costimulatorybispecificantibodiesinduceenhancedtcellactivationandtumorcellkillinginbreastcancermodels AT lucknermindenclaudia costimulatorybispecificantibodiesinduceenhancedtcellactivationandtumorcellkillinginbreastcancermodels AT ziegelmeierclaudia costimulatorybispecificantibodiesinduceenhancedtcellactivationandtumorcellkillinginbreastcancermodels AT heusselclauspeter costimulatorybispecificantibodiesinduceenhancedtcellactivationandtumorcellkillinginbreastcancermodels AT zorniginka costimulatorybispecificantibodiesinduceenhancedtcellactivationandtumorcellkillinginbreastcancermodels AT jagerdirk costimulatorybispecificantibodiesinduceenhancedtcellactivationandtumorcellkillinginbreastcancermodels AT momburgfrank costimulatorybispecificantibodiesinduceenhancedtcellactivationandtumorcellkillinginbreastcancermodels |